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apresentação gráﬁca do conteúdo textual (veriﬁcadas no estudo analítico) podem 
inﬂuenciar negativamente nas estratégias de leitura da bula, particularmente pelos 
participantes com pouca experiência de leitura com este tipo de documento. CON-
CLUSÕES: Com base nos resultados de ambos os estudos foram elaboradas diretrizes 
e espera-se que estas possam contribuir com a melhoria na qualidade da estrutura e 
apresentação gráﬁca do conteúdo textual da bula de medicamento no Brasil.
PIH13
THE IMPACT OF FAMILY PHYSICIAN PROGRAM ON HEALTH 
INDICATORS IN IRAN (2003–2007)
Barati O
Iran University of Medical Science, Tehran, Iran
OBJECTIVES: “ Family Physician” program has been launched since 2005 as a fun-
damental health plan in Iran. In spite of valuable information gathered through vital 
horoscope, only a few studies have been done in order to evaluate the performance 
of this program. So this research has been carried out to assess the impact of this 
program on heath indicators. METHODS: The research involved collecting data about 
11 main health indicators extracted from the ofﬁcial annual report of the deputy for 
health from 2001 to 2006 and analyzing them through t- paired test in SPSS RESULTS: 
Statistical analysis shows that the changes in 6 main indicators during these years 
including infant mortality rate, (IMR), crude birth rate, under-5 mortality rate 
(U5MR), neonatal mortality rate (NMR), maternal mortality rate (MMR), and per-
centage of deliveries attended by unskilled persons were signiﬁcant (p-value  0/05) 
and all of the above indicators have decreased during these years. Although other 5 
indicators such as crude death rate(CDR), general fertility rate, percentage of deliveries 
in hospitals, percentage of family planning coverage and still birth rate had an appro-
priate improvement during these years, their changes were not statistically signiﬁcant 
(p-value  0/05). CONCLUSIONS: Findings indicates that there is an acceptable 
improvement in many of the health indicators since starting this program. But this 
does not mean that the other factors that might have affect on these indicators should 
not be considered.
INFECTION – Clinical Outcomes Studies
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CARDIOVASCULAR RISK AMONG BRAZILIAN HIV-INFECTED PATIENTS 
ON HAART: RAPID II STUDY
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OBJECTIVES: Gender differences in cardiovascular risk (CVR) among HIV-infected 
patients have been reported, with conﬂicting results. We have previously reported data 
from the Registry and Prospective Analysis of Patients Infected with HIV and Dyslip-
idemia (RAPID II study) a higher CVR in males and higher rates of obesity, metabolic 
syndrome (MS), and lack of physical exercise in females. We now compare gender 
differences among Brazilian individuals METHODS: Adult HIV-infected patients with 
at least 6 months of HAART were enrolled in this longitudinal study that is being 
conducted in 7 countries. Metabolic proﬁle, anthropometric parameters, CD4-cell 
count, viral load (VL), types of HAART, CVR factors, and Framingham score were 
compared by gender RESULTS: A total of 1001 Brazilian patients were enrolled, 655 
(65.4%) were males. Mean (SD) age was 44 (10) years, mean time on HAART was 
48.4(36.4) months, 48% were on a protease inhibitors-based HAART, mean CD4-cell 
count was 519 (274) cells/mm3, and mean VL was 2.29 (0.9) log10 copies/ml. Males 
were found to have higher 10-year CVR (15.9 o 30.1 vs 11.0 o 29.6; P  0.0136) and 
were more likely to belong to the high-risk category (15.9% vs 10.4%; P  0.021) 
than females. No gender differences were found in the rates of hypertension, type II 
diabetes, or MS. Female patients showed higher prevalence of obesity (12.7% vs 7.2%; 
P  0.005) and physical inactivity (66.5% vs 53.6%; P  0.001) than males. In con-
trast, male patients were older (44.5 o 9.4 vs 43.0 o 10.4 years; P  0.0194), and had 
higher rates of smoking (24.4% vs 17.6%; P  0.016) and dyslipidemia (81.8% vs 
74.6%; P  0.009) than females CONCLUSIONS: Brazilian individuals sheds light 
on gender differences whose recognition may be important for appropriate interven-
tion on modiﬁable CVR factors.
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INTEGRATION OF PHARMACO-ECONOMIC OUTCOME BASED 
RESEARCH WITH LOCAL CONTEXT: A MODEL FOR RATIONAL 
HEALTH CARE DECISION-MAKING IN DEVELOPING COUNTRIES
Mathew JL
Postgraduate Institute of Medical Education and Research, Chandigarh, India
BACKGROUND: Extrapolation of research data from developed countries, without 
considering the local context can sometimes result in outcomes different from the 
research setting, emphasizing the need to integrate external research with local context. 
An example of hepatitis B vaccination in India is presented as a model. OBJECTIVES: 
To decide whether hepatitis B vaccination should be introduced in India, by integrating 
pharmaco-economic research data with the local context. METHODS: Detailed 
literature search was undertaken to identify evidence for: 1) hepatitis B disease burden 
in India; 2) efﬁcacy and safety of Hepatitis B vaccination; 3) economic implications; 
4) feasibility of universal administration; 5) local situation; and 6) expected short and 
long term outcome. Evidence was sought in the following hierarchy: systematic 
reviews, randomized trials and case control/cohort studies. RESULTS: A current sys-
tematic review1 identiﬁed Hepatitis B prevalence as 1.7%; another (Cochrane) 
review2 reported relative risk of hepatitis B following vaccination as 0.12(0.03–0.44) 
in per-protocol analysis, suggesting that prevalence could be decreased by 88% 
through universal vaccination. The cost of vaccine would be approximately 0.15US$ 
per dose and vaccination cost per child approximately 0.60US$ (1.8US$ for three 
doses) if added to DPT vaccination administered to infants at 6,10,14 weeks of age; 
thereby making the intervention highly cost-effective in terms of reduction in disease 
prevalence (short-term outcome) and hepatitis B morbidity/mortality (long-term 
outcome). However current national data3 shows that DPT vaccine coverage is only 
55.3%; further over one-third of hepatitis B infection is acquired perinatally4 and 
cannot be prevented through this vaccination schedule. Therefore, integrating local 
context with research data suggests that the expected 88% reduction in prevalence 
(from research data) would practically translate to only 37% reduction, whereby 
hepatitis B vaccination may no longer be cost-effective to reduce disease burden. 
CONCLUSIONS: It is critical to incorporate local contextual issues when pharmaco-
economic outcome data is extrapolated from external research, especially in develop-
ing countries.
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OBJECTIVES: The objective of this analysis was to apply a risk estimation model 
(REVEAL study by Chen, 2007) to predict HCC development in Brazilian CHB-
infected subjects and to estimate the level of risk according to Viral Load distribution. 
METHODS: We evaluated: gender, age, family history of HCC, prevalence of alcohol 
consumption, ALT, HBeAg and HBV DNA levels. Patients were from different regions 
of Brazil, diagnosed with CHB at the DASA in 2007. Regression coefﬁcients derived 
from the Cox models of Chen’s study were converted into risk scores (RS) and the 
predicted risks of HCC over 5 and 10 years calculated by predicted 5/10 years HCC 
risk  1-(1-P0) exp (RS-RS0); being: P0: Predicted probability of HCC within 5/10 
years for persons with the reference-level risk score RS0 and RS: Risk score of which 
HCC risk to be predicted. Costs for treatment was reported by Castelo (2007). 
RESULTS: Of the total population (564) 64.5% were males and 62.1% were HBeAg 
negative. The median HBV DNA level was 1,789 and 72,924 copies/mL for HBeAg 
negative and positive patients, respectively. Patients male, older with high HBV DNA 
levels had the greatest risk of developing HCC. The mean (SD) estimated risk for 5 
and 10 years in 1000 patients are 7.87 (6.82) and 18.30 (15.77), respectively. In 
patients older than 40 years old this risk is 27.34 (13.82) and for patients with HBV 
DNA levels higher than 10,000, the risk is 26.54 (15.75). The costs for treating these 
patients can vary from US$34,861.50 to US$50,558.70, if these patients are trans-
planted these costs can be from US$639,548.40 to US$927,519.92. CONCLUSIONS: 
This study suggests that the risk of HCC in the Brazilian HBV population is consider-
able and may signicantly impact the health care system.
INFECTION – Cost Studies
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DATABASE) FROM MINISTRY OF HEALTH
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OBJECTIVES: The distribution of Chronic hepatitis B virus (HBV) in various Brazil-
ian regions is not well understood. The public health and economic impact of Hepatitis 
B and its complications such as cirrhosis, and liver cancer in the Brazilian Uniﬁed 
Health System (SUS) will give further insights of the importance of the disease in 
Brazil. DATASUS is a public administrative database maintained by MoH and can 
contribute to the study of HBV. METHODS: HBV and its complications in the Brazil-
ian SUS was evaluated in the public database DATASUS between 2000 to 2007. Data 
were tabulated according with different Brazilian states. RESULTS: Mortality data 
indicate a peak of viral hepatitis and liver cirrhosis between 40 to 60 years old, fol-
lowed by another mortality peak due to liver cancer between 60 to 80 years old, this 
pattern is found in the states studied. The average hospitalization time for liver-related 
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disease is 9.16 days as compared with 5.83 days to all-causes hospitalizations. In 
some states, such as Minas Gerais and Federal District (Brasilia), a greater rate of 
Hospitalization authorizations (AIH) for liver-related diseases was observed compared 
to the rate for all-causes hospitalization. Lamivudine is the treatment of choice com-
pared with interferon and others therapies, particularly after 2003 when lamivudine 
was included in the high cost list and made available for SUS. The costs for SUS is 
steadily increasing with liver transplant and immunosuppressive drugs in several 
states. For example, SUS expend R$4,560,00 with transplants and more than 
R$100,000,000 with immunosuppresion in 2006. CONCLUSIONS: HBV and 
its complications exert a signiﬁcant clinical and economic impact to the Brazilian 
Public Health System and suggest that existing therapies are inadequate to address 
the issue.
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CARGA FINANCIERA POR HEPATITIS A EN MÉXICO
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OBJECTIVOS: La hepatitis A es una de las enfermedades virales más comunes que 
constituye un problema de salud pública en México. Se ha demostrado que la inci-
dencia de la infección se ha estado desplazando a edades mayores, donde las conse-
cuencias clínicas son más severas y más costosas. El objetivo de este estudio es 
determinar los costos de tratamiento de Hepatitis A y sus complicaciones, así como 
la carga ﬁnanciera que ocasiona este padecimiento en México. METODOLOGÍAS: 
Se realizó un estudio en el que se llevó a cabo la revisión retrospectiva de expedientes 
clínicos de pacientes con diagnóstico de hepatitis A atendidos en cinco clínicas de 
segundo y tercer nivel del sector público de México. Par la recolección de la 
información, se desarrolló un instrumento que permitió recolectar los costos unitarios 
y utilización de recursos médicos utilizados en la atención de pacientes con hepatitis 
A y sus complicaciones, hepatitis colestásica, hepatitis fulminante. Para determinar la 
carga ﬁnanciera anual se combinaron los costos estimados por caso con la incidencia 
anual correspondiente. RESULTADOS: El costo total anual estimado de hepatitis A 
y sus complicaciones fue de $75,972,381 pesos ($8,830,003–$237,005,243). El costo 
por caso de hepatitis A ligera fue de $1,186 ($192–$4,183) pesos, de $5,942 ($365–
$25,125) para hepatitis A grave, de $9,967 ($1,193–$18,740) en colestásica y $55,798 
($14,462–$97,134) en fulminante. CONCLUSIONES: Los resultados sugieren una 
alta carga ﬁnanciera ocasionada por el aumento en la severidad de los casos, la deter-
minación de los costos por caso será útil para conocer el impacto económico de la 
introducción de medidas preventivas como es la vacunación.
PIN6
COSTS OF NOSOCOMIAL PNEUMONIA IN A THIRD LEVEL HOSPITAL 
OF MEXICAN SOCIAL SECURITY INSTITUTE (IMSS)
Ortega-Alvarado S, Hernandez-Guerrero AT, Aviles-Hernández R, Vazquez-Pavon LE, 
Ambriz-Nava LP
Instituto Mexicano de Seguro Social, Mexico City, Mexico
OBJECTIVES: To estimate direct medical costs of management of nosocomial pneu-
monia (NP) and ventilator-associated nosocomial pneumonia (VAP) in General Hos-
pital (GH) of Raza National Medical Center METHODS: Data from nosocomial 
pneumonia patients who diagnosed according to Mexican Ofﬁcial Standard Nom-
026-SSA2-1998 and received medical assistance in GH between 2006–08 were include 
in the study. The clinical response was used to assess clinical status (fail or successful 
in the ﬁrst treatment). Costs were estimated from the hospital perspective using a 
bottom-up approach, and only direct medical costs were estimated (hospitalization, 
treatment, laboratory tests, specialist visit). Clinical data and resource utilization were 
obtained from individual clinical. The unitary costs used are those ofﬁcially published 
by IMSS. A 5% discount rate was used, and costs were adjusted as to 2008. Results 
are shown as mean standard (SD) and pesos mexicans. Generalized Linear Model 
analysis was applied. Sensitivity analyses included variation of the main variables 
RESULTS: 113 patients were included, 70 with NP and 43 patients with VAP. Male 
62%, age 57 o 18 years, patients with NP and VAP due to Pseudomonas aeruginosa 
were 34%. Mortality were 24%. Patients with VAP who fail ﬁrst treatment were 68% 
vs NP 53% (p  0.03). More resources were utilized for VAP patients compared 
to NP in length of stay in days in intensive care unit 8.64 vs 3.7 days respectively 
(p  0.0001). Average VAP costs per fail patient in ﬁrst treatment were higher 
than successful patients MXN$279,619.6 vs $190,908.7(p  0.0001). In NN hap-
pened same situation $172,411.2 vs $132,306.4 (p  0.001). 93% and 96% of 
total costs were due to hospitalization in patients with NP and VAP, respectively 
CONCLUSIONS: Strategies should be looked for to obtain better results since 
the ﬁrst scheme of treatment with this type of patients to avoid incremental cost of a 
fail patient.
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COSTO-BENEFICIO DEL USO DE TIGECICLINA VS. TRIPLE ESQUEMA 
ANTIMICROBIANO CEFOTAXIMA/AMIKACINA/METRONIDAZOL EN 
PACIENTES CON INFECCIONES INTRAABDOMINALES Y DE PIEL Y 
TEJIDOS BLANDOS EN MÉXICO
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OBJECTIVOS: Evaluar los costos y beneﬁcios asociados a dos esquemas anti-
microbianos en la atención de infecciones intraabdominales y de piel y tejidos 
blandos: tigeciclina vs. el triple esquema cefotaxima//metronidazol/amikacina. 
 METODOLOGÍAS: Se realizó una búsqueda bibliográﬁca con tigeciclina a ﬁn de 
conocer las medidas de respuesta al tratamiento, los esquemas y dosis administrados. 
Se determinaron los costos directos médicos desde el punto de vista del Sector Salud 
en México. Los precios unitarios de los medicamentos e insumos incluidos fueron 
obtenidos de la lista oﬁcial de precios del sector salud. Para identiﬁcar el consumo de 
recursos médicos se integró un panel de expertos. Los costos unitarios fueron obteni-
dos de los listados oﬁciales de esas instituciones. RESULTADOS: En términos de 
costos totales por paciente, el tratamiento con tigeciclina tiene un costo total de 
$73,708 y de $91,830 para el 2° y 3° nivel de atención respectivamente, durante un 
período de estancia de 7 días, y de $147,416 y de $183,660 para el 2° y 3° nivel 
respectivamente, durante un período de estancia de 14 días. En el caso de estar sujetos 
a un triple esquema y considerando una estancia hospitalaria mínima de 14 días, los 
costos totales con el triple esquema serían de $155,243 y de $209,299 para el 2° y 3° 
nivel de atención respectivamente. Bajo un escenario donde los pacientes pueden llegar 
a permanecer 6 semanas hospitalizados en casos muy severos, se tiene un costo total 
de $465,730 y $627,898 para el 2° y 3° nivel de atención respectivamente. CONCLU-
SIONES: Tigeciclina proporciona ahorros importantes a consecuencia de una dismi-
nución en las re-intervenciones quirúrgicas, ya que por tener un perﬁl de resistencia 
menor, la extensión y profundidad del proceso infeccioso se resuelve en menor 
tiempo.
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EVALUACIÓN DEL IMPACTO EPIDEMIOLÓGICO Y ECONÓMICO DE LA 
INTRODUCCIÓN DE LA VACUNA DE ROTAVIRUS EN EL PAÍS DE 
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de La Hoz F1, Alvis N2, Cediel N3, Narváez J1, Orozco J4, Alvis L2
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OBJECTIVOS: Estimar la carga de enfermedad diarreica aguda (EDA) y enfermedad 
atribuible a rotavirus en menores de dos años, y modelar el impacto epidemiológico 
y económico de la introducción de la vacuna de rotavirus en Colombia. 
 METODOLOGÍAS: 1. Revisión sistemática y análisis descriptivo de la literatura 
nacional e internacional y de fuentes de información no publicadas y 2. Estudio de 
evaluación económica del impacto de la introducción de la vacuna. RESULTADOS: 
Se estima que en el 2007 en Colombia ocurrieron aproximadamente: 2,737,794 (IC95% 
2,421,178–2,979,911) casos de diarrea en menores de 2 años, de los cuales 98,049 
(IC95% 86,710–106,719) requirieron hospitalización. Se estimaron 328,535 casos 
ocasionados por el rotavirus, 108,417 (IC95% 78,446–132,308) consultas ambulato-
rias atribuibles al rotavirus, 37,258 (IC95% 26,013–45,889) hospitalizaciones y 
entre 295 y 560 muertes por diarrea debida a rotavirus. Los costos de la carga de 
enfermedad por EDA en Colombia, en ausencia de un programa de vacunación 
contra rotavirus, equivalen a US$30.9 millones (US$27.3–US$33.6 de 2007) que cubren 
gastos de atención médica y costos indirectos representados por la perdida de produc-
tividad de padres o acompañantes. Los costos anuales evitados por el programa 
de vacunación podrían estar entre US$5.7 y US$8.1 millones, es decir, una disminución 
del 18.5% al 26% de los costos totales ocasionados por la EDA en Colombia. 
La vacunación presenta una razón de costo efectividad incremental de US$ 500 
por año de vida salvado y US$34,985 por muerte evitada. CONCLUSIONES: 
En Colombia, la vacuna contra el rotavirus es muy costo efectiva, ya que la relación 
costo efectividad calculada es menor que el valor del PIB per cápita, evaluado en 
US$3229 para el 2007. Se recomienda considerar la introducción de esta vacuna en 
el territorio nacional.
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MODELO FARMACOECONÓMICO VORICONAZOL EN ASPERGILOSIS 
INVASIVA: CASO VENEZUELA
Castro Mendez JS1, Fandiño Pico C2
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OBJECTIVOS: La alta mortalidad asociada al aumento de la enfermedad invasiva 
fungica hace que sea muy importante la evaluación del costo-efectividad de las diversas 
estrategias en tratamiento de estas patologías sobre todo teniendo en consideración la 
toxicidad de los esquemas tradicionales. METODOLOGÍAS: Se realizó un modelo de 
costo efectividad basado en la metodología de análisis de decisión comparando dos 
estrategias de tratamiento en aspergillosis invasiva a saber : Anfotericina B Deoxico-
lato frente a Voriconazol. Para ello se asumieron : 1)Las probabilidades de efectividad 
terapéuticas fueron basadas en estudios de referencia publicados 2) Los costos directos 
de tratamiento fueron basado en tratamiento de enfermedad fúngica invasiva en 
entorno de hospital privado 3) Modelo matemático realizado en Excel 2003 con las 
siguientes características : Horizonte temporal de 12 semanas (ambulatorio  hospi-
talizado) 4) Probabilidad de valor ﬁjo 5) Perspectiva de pagador 6) solo costos direc-
tos, los pacientes en falla clínica se manejaron con esquemas de antifungicos varios. 
Se calculo el costo total por estrategia, costo promedio por paciente, costo de caso 
exitoso, costo de caso con falla primaria y costo porcentual imputable a antifungicos 
dentro del esquema. Se realizó análisis de sensibilidad basado en variabilidad 10%. 
RESULTADOS: El costo promedio de paciente tratado con Anfotericina B Deoxico-
lato fue de US$23,827 frente a Voriconazol US$19,361, el costo por sobreviviente en 
Anfotericina B deoxicolato fue de US$65,453 frente a US$36,695. CONCLUSIONES: 
La estrategia predominante en base al costo–efectividad seria Voriconazol para trata-
miento de aspergillosis.
